The following criteria is provided for health care professionals.
Inclusion Criteria:
- Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. Patients will be considered high-risk if they have any of the following:
- Age > 50 years
- ECOG Performance status of <2
- Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st CR; second or greater CR, 1st relapse; any ph+ ALL
- CML 2nd chronic phase, accelerated phase, or blastic phase
- MDS with IPS of Intermediate 2 or greater
- Any myeloproliferative disorder
- Hodgkin lymphoma: relapsed, refractory, or primary induction failure
- Non-Hodgkin lymphoma: relapsed, refractory, primary treatment failure, or not eligible for an autologous HSCT
- Other conditions not listed will be assessed as high-risk by the PI
- Patients must have a related donor who is either HLA-identical or a one antigen mismatch at the HLA- A; B; C; and DR loci.
- Patients must adequate organ function:
- LVEF of >45%
- DLCO (adjusted for hemoglobin) >45% of predicted
- Adequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal
- Creatinine clearance of > 60 ml/min
- Patients must be willing to use contraception if they have childbearing potential
- Able to give informed consent
Exclusion Criteria:
- ECOG performance status of 3 or 4.
- HIV positive
- Active involvement of the central nervous system with malignancy
- Psychiatric disorder that would preclude patients from signing an informed consent
- Pregnancy
- Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder.